Combined Therapeutic Effect of Probucol and Cilostazol on Endothelial Function in Patients with Silent Cerebral Lacunar Infarcts and Hypercholesterolemia

Combined Therapeutic Effect of Probucol and Cilostazol on Endothelial Function in Patients with Silent Cerebral Lacunar Infarcts and Hypercholesterolemia - Probucol, cilostazol and endothelial function in SLCI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220138

Enrollment

Registered

2013-09-12

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Investigating the effect of combined therapy with probucol and cilostazol on endothelial function in patients with cerebral infarction and hypercholesterolemia.

Interventions

Intervention type:DRUG Name of intervention: combined therapy with probucol and cilostazol Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application:ORAL Do

cilostazol 200mg daily mg Dosing frequency / Frequency of use:BID probucol,500mg

cilostazol 200mg daily Planned duration of intervention:4 weeks Intended dose regimen:probucol,500mg

cilostazol 200mg daily detailes of teratment arms:the patients with silent lacunar cerebral infarcts and mild hypercholesterolemia Comparative intervention name:aspirin (100 mg/day) prescription group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: lacunar cerebral infarct diagnosed by MRI and hypercholesterolemia (LDL >140mg/gL)

Exclusion criteria

Exclusion criteria: allergic reaction to probucol, cilostazol, or aspirin or any other acute and/or severe disorders

Design outcomes

Primary

Measure	Time frame
endothelial function	—

Secondary

Measure	Time frame
Presence of side effect	—

Countries

Japan

Contacts

Public ContactTakase Bonpei

National Defense Medical College

bonpeit@ndmc.ac.jp+81-4-2994-1511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026